Jonathan A. Fletcher

TL;DR: A recurrent oncogenic mechanism is reported, in IMTs, in which tropomyosin N-terminal coiled-coil domains are fused to the ALK C- terminal kinase domain, the first known fusion oncogene that transforms, in vivo, both mesenchymal and lymphoid human cell lineages.

TL;DR: The role of HER-2/neu testing for the prediction of response to trastuzumab therapy in breast cancer is presented as well as its potential impact on responses to standard and newer hormonal therapies, cytotoxic chemotherapy, and radiation.

TL;DR: Findings indicate that KIT may be activated by mutations in at least three domains-extracellular, juxtamembrane, and kinase-in GISTs.

TL;DR: Evidence is presented that the ras proteins in malignant tumour cell lines from patients with type 1 neurofibromatosis are in a constitutively activated state, as judged by the guanine nucleotide bound to them, and are necessary for cellular proliferation, and support the hypothesis that NF1 is a tumour-suppressor gene whose product acts upstream of ras.

TL;DR: In this paper, a translocation involving a single gene family, consisting of EWS and related genes, has been identified in five different sarcomas, and its chimeric protein products could prove similarly amenable to inhibitors.